Lumateperone
Caplyta
Second-Generation Antipsychotic (SGA)
The mechanism of action of lumateperone could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors, partial agonist activity at central dopamine D2 receptors, and moderate serotonin transporter (SERT) inhibition. At therapeutic doses (42 mg), cortical 5-HT2A receptor occupancy exceeds 80% while striatal D2 occupancy is only ~39%, producing antipsychotic efficacy with minimal EPS. Low affinity for muscarinic and histaminergic receptors contributes to a favorable metabolic and sedation profile relative to other SGAs.
Compare Lumateperone →FDA-Approved Indications
- Schizophrenia in adults
- Bipolar depression (bipolar I or II) in adults — monotherapy or adjunctive with lithium/valproate
- Major depressive disorder in adults — adjunctive with antidepressants
Common Off-Label Uses
- Agitation in Alzheimer dementia (Phase 3 trial discontinued but clinical interest remains)
- Treatment-resistant schizophrenia adjunct (clinical experience)
What Sets This Drug Apart
- Only SGA FDA-approved for three indications: schizophrenia, bipolar depression, and MDD adjunct
- Unique triple mechanism: 5-HT2A antagonism + D2 partial agonism + SERT inhibition at therapeutic doses
- Very low D2 occupancy (~39% at 42 mg) vs conventional antipsychotics, contributing to minimal EPS (similar to placebo on SAS/BARS/AIMS)
- Weight neutral to slight weight loss in long-term data (mean -2 to -3.2 kg at 6-12 months)
- Low muscarinic and histaminergic binding (less than 50% inhibition at 100 nM) — minimal anticholinergic burden
- CYP3A4 substrate requiring dose adjustment with CYP3A4 inhibitors and avoidance of inducers — limits co-prescribing flexibility
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis — not approved for this use
Boxed Warning
Suicidal thoughts and behaviors in pediatric and young adult patients — monitor closely